Diabeto-Cardiology : A Companion to Braunwald's Heart Disease (Companion to Braunwald's Heart Disease) (2ND)

個数:
電子版価格
¥76,501
  • 電子版あり

Diabeto-Cardiology : A Companion to Braunwald's Heart Disease (Companion to Braunwald's Heart Disease) (2ND)

  • 提携先の海外書籍取次会社に在庫がございます。通常3週間で発送いたします。
    重要ご説明事項
    1. 納期遅延や、ご入手不能となる場合が若干ございます。
    2. 複数冊ご注文の場合は、ご注文数量が揃ってからまとめて発送いたします。
    3. 美品のご指定は承りかねます。

    ●3Dセキュア導入とクレジットカードによるお支払いについて
  • 【入荷遅延について】
    世界情勢の影響により、海外からお取り寄せとなる洋書・洋古書の入荷が、表示している標準的な納期よりも遅延する場合がございます。
    おそれいりますが、あらかじめご了承くださいますようお願い申し上げます。
  • ◆画像の表紙や帯等は実物とは異なる場合があります。
  • ◆ウェブストアでの洋書販売価格は、弊社店舗等での販売価格とは異なります。
    また、洋書販売価格は、ご注文確定時点での日本円価格となります。
    ご注文確定後に、同じ洋書の販売価格が変動しても、それは反映されません。
  • 製本 Hardcover:ハードカバー版/ページ数 416 p.
  • 言語 ENG
  • 商品コード 9780323878623
  • DDC分類 616.12

Full Description

Part of the renowned Braunwald family of references, Diabeto-Cardiology, 2nd Edition, provides today's clinicians with clear, authoritative guidance on the complex challenges of providing care to patients with cardiovascular and diabetes co-morbidities. Drs. Darren K. McGuire and Nikolaus Marx, along with a leading team of experts in cardiology and diabetes, address both the foundational aspects and clinical implications for this growing number of patients, including recent breakthrough therapies and new medications that have contributed to newer and more effective treatments and improved patient outcomes. From cover to cover, this second edition offers reliable and current point-of-care coverage of the interwoven care needs of patients with these complex co-morbidities, making it an ideal resource for practitioners at all levels of experience.

Discusses cutting-edge therapeutic approaches to the medical care of cardiology patients with diabetes, combining coverage of the latest understanding of the complex relationship between diabetes and cardiovascular disease with recent clinical advances.
Offers a contemporary, clinical focus based on a new understanding of underlying pathologies, as well as application of evidence from clinical trials that have dramatically changed treatment and affected both cardiology and endocrinology practice.
Includes state-of-the-art coverage of antihyperglycemic medications that have demonstrated efficacy to reduce risk for atherosclerotic cardiovascular disease, heart failure, and kidney disease progression, that have affected a revolution of therapy in both cardiology and endocrinology.
Features a practical, concise presentation with a focus on actionable clinical content, including new Clinical Practice Points and Take Home Summaries.
An eBook version is included with purchase. The eBook allows you to access all of the text, figures and references, with the ability to search, customize your content, make notes and highlights, and have content read aloud. Additional digital ancillary content may publish up to 6 weeks following the publication date.

Contents

PART I DIABETES MELLITUS
1 Definition and Epidemiology of Type 2 Diabetes Mellitus
2 Insulin Resistance: Pathophysiology, Molecular Mechanisms, and Genetic Insights
3 Lifestyle Interventions for the Prevention of Type 2 Diabetes Mellitus
4 Pharmacological and Surgical Interventions That Prevent or Remit Type 2 Diabetes
5 Type 1 Diabetes: Pathophysiology and Treatment Considerations for Cardiovascular Risk and Disease
PART II CARDIOVASCULAR COMPLICATIONS OF TYPE 2 DIABETES
6 Epidemiology of Diabetes Mellitus and Atherosclerotic Cardiovascular Disease
7 Pathology and Vascular Biology of Atherosclerosis in Patients With Type 2 Diabetes
8 Risk Stratification Among Patients With Type 2 Diabetes With or at Risk for Atherosclerotic Cardiovascular Disease
9 Epidemiology and Pathophysiology of Heart Failure With Preserved and With Reduced Ejection Fraction in Patients With Type 2 Diabetes
PART III EFFECTS OF ANTIHYPERGLYCEMIC THERAPIES FOR TYPE 2 DIABETES ON CARDIOVASCULAR AND KIDNEY OUTCOMES
10 Effect of Glucose Management on Coronary Heart Disease Risk in Patients With Type 2 Diabetes
11 Regulatory Approach to Medications for Type 2 Diabetes: Past, Present, and Future
12 Cardiovascular and Kidney Effects of Sodium Glucose Cotransporter Inhibitors
13 Cardiovascular and Kidney Effects of Glucagon-Like Peptide 1 Receptor Agonists
14 Antihyperglycemic Medications With Proven Cardiovascular Safety
15 Prevention of Heart Failure in People With Diabetes
16 Treatment of Patients With Reduced and With Preserved Ejection Fraction Heart Failure in Patients With Type 2 Diabetes
PART IV MANAGEMENT OF CORONARY HEART DISEASE RISK CHRONIC AND ACUTE CORONARY SYNDROMES IN PATIENTS WITH TYPE 2 DIABETES
17 Effect of Lifestyle Interventions on Coronary Heart Disease Risk in Patients With Type 2 Diabetes
18 Effect of Blood Pressure Management on Coronary Heart Disease Risk in Patients With Type 2 Diabetes
19 Effect of Lipid Management on Coronary Heart Disease Risk in Persons With Type 2 Diabetes
20 Effect of Antithrombotic Therapy on Coronary Heart Disease Risk in People With Diabetes Mellitus
21 Role of Percutaneous Coronary Intervention in Patients With Diabetes
PART V OTHER CARDIOVASCULAR CONSIDERATIONS FOR PATIENTS WITH TYPE 2 DIABETES
22 Peripheral Artery Disease in Persons With Type 2 Diabetes
23 Cerebrovascular Disease in Persons With Diabetes
24 Atrial Fibrillation in Persons With Type 2 Diabetes
25 Chronic Kidney Disease: Implications for Cardiovascular Risk and Management in Patients With Type 2 Diabetes
26 Disparities in Type 2 Diabetes Risk, Cardiovascular Consequences, and Care: Females, Racial/Ethnic Minorities, and the Elderly
27 The Quality Chasm and the Need for Implementation Science to Reduce Cardiovascular Disease Risk in Type 2 Diabetes

最近チェックした商品